PHR250117P17500
- 0.14
- 0.000.00%
Phreesia Newsroom
Citigroup Maintains Buy on Phreesia, Raises Price Target to $35
Needham Maintains Phreesia(PHR.US) With Buy Rating, Maintains Target Price $29
Needham Reiterates Buy on Phreesia, Maintains $29 Price Target
Phreesia's Growth Potential and Balanced Strategy Justifies Buy Rating
Phreesia Is Maintained at Overweight by Keybanc
Phreesia Analyst Ratings
KeyBanc Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $30
RBC Capital Upgrades Phreesia(PHR.US) to Buy Rating, Raises Target Price to $32
D.A. Davidson Maintains Phreesia(PHR.US) With Buy Rating, Announces Target Price $36
Phreesia (PHR) Receives a Buy From J.P. Morgan
RBC Capital Sticks to Its Hold Rating for Phreesia (PHR)
Analysts Offer Insights on Healthcare Companies: Pharming Group (OtherPHGUF) and Phreesia (PHR)
Truist Financial Maintains Phreesia(PHR.US) With Buy Rating, Announces Target Price $34
Phreesia Price Target Raised to $34.00/Share From $31.00 by Truist Securities
Phreesia Is Maintained at Buy by Truist Securities
Truist Financial Initiates Phreesia(PHR.US) With Buy Rating, Announces Target Price $34
A Quick Look at Today's Ratings for Phreesia(PHR.US), With a Forecast Between $28 to $30
Baird Maintains Outperform on Phreesia, Lowers Price Target to $30
A Quick Look at Today's Ratings for Phreesia(PHR.US), With a Forecast Between $29 to $34
Optimistic Buy Rating for Phreesia: Margin Expansion, Strategic Growth, and Ambitious Profit Goals Drive Positive Outlook